L-dopa: synonym for levodopa in Parkinson's disease
L-dopa is the common synonym for levodopa, the most effective substance in the therapy of Parkinson's disease. The term refers to the levorotatory (L) form of 3,4-dihydroxyphenylalanine (dopa), a natural precursor of the neurotransmitter dopamine. The hyphenated spelling (L-dopa) follows biochemical convention to indicate stereochemistry. Pharmacologically, L-dopa is identical with levodopa.
Levodopa was first successfully used in 1961 to treat Parkinson's symptoms. Despite many follow-on substances, it remains the gold standard for motor symptoms, especially in advanced stages. Commercial preparations always combine L-dopa with a peripheral DOPA decarboxylase inhibitor (carbidopa or benserazide), which increases CNS bioavailability and reduces peripheral side effects.
Mechanism of action
L-dopa is actively absorbed in the small intestine via the large neutral amino acid transporter (LAT 1). The substance crosses the blood-brain barrier likewise via LAT 1 and is converted in the striatum by the enzyme DOPA decarboxylase (aromatic L-amino acid decarboxylase) to dopamine. Dopamine fills the depleted stores of dying dopaminergic neurons of the substantia nigra and restores near-physiological neurotransmission.
Carbidopa or benserazide inhibit peripheral DOPA decarboxylase without crossing the blood-brain barrier. This prevents L-dopa being converted to dopamine in peripheral tissue. Effects such as nausea, hypotension and tachycardia are reduced; the levodopa dose can be lowered by about 75 % for the same central effect.
Over years of therapy, the duration of a single dose decreases (wearing off) and movement disorders (dyskinesias) appear. These motor complications are caused not by L-dopa itself but by the progression of the disease and the pulsatile stimulation of dopaminergic receptors.
Indications
- Idiopathic Parkinson's disease: main indication, in all stages of the disease
- Atypical parkinsonian syndromes: often less effective, but can be tried for diagnosis or symptomatic relief
- Restless legs syndrome: at low dose for intermittent symptoms
- Off-label: dopa-responsive dystonia (Segawa syndrome)
Dosing and administration
Standard daily dose: 300 to 800 mg L-dopa, divided into 3 to 5 doses. Stepwise titration over 2 to 4 weeks.
Restless legs syndrome: 50 to 200 mg before bedtime.
Application tips:
- Take 30 to 60 minutes before meals, since amino acids from protein impair absorption
- For gastrointestinal complaints, intake with a small carbohydrate-rich snack is possible
- Plan daily protein intake, often shifted to the evening (protein-redistribution diet)
- Sustained-release preparations (Madopar Depot, Sinemet CR) for more stable levels, especially at night
- Orodispersible tablets or solution for rapid effect in off phases
In advanced stages, continuous levodopa-carbidopa via jejunal tube (Duodopa) or pump (foslevodopa-foscarbidopa subcutaneously) can be sensible.
Side effects
Common: nausea, vomiting, orthostatic hypotension, dyskinesias (chorea-like movements), dry mouth, sleep disturbance, vivid dreams, reddish-brown discoloration of urine and sweat.
Common during course: motor fluctuations (wearing off, on-off phenomena), non-motor symptoms such as hallucinations, confusion, impulse-control disorders (gambling, hypersexuality).
Rare: neuroleptic malignant-like syndrome on abrupt discontinuation, severe cardiovascular reactions, somnolence attacks, marked hallucinations, anaemia, leukopenia.
Important points:
- Nausea and orthostatic hypotension mostly at the start of therapy, improving over time
- Dyskinesias usually appear after several years of therapy
- Do not stop abruptly due to risk of malignant-like syndrome
- Take impulse-control disorders seriously, ask regularly; patients are often ashamed
Interactions
- Classic MAO inhibitors: risk of hypertensive crisis, combination contraindicated
- Selective MAO-B inhibitors (selegiline, rasagiline): clinically usable to prolong effect
- Antipsychotics (except clozapine and quetiapine): antagonistic action at the dopamine receptor, worsening Parkinson's symptoms
- Metoclopramide: antagonistic dopaminergic effect, contraindicated
- Iron preparations: reduced absorption through complex formation, minimum 2-hour interval
- Protein-rich meals: reduced absorption
- Reserpine: antagonistic effect, avoid combination
- Anaesthesia with halothane: risk of arrhythmias
Special considerations
Pregnancy and breastfeeding: data limited, individual judgement. Registry data on pregnancies show no increased malformation risk.
Narrow-angle glaucoma: caution.
Surgery: do not interrupt therapy if possible, especially not abruptly. For emergency surgery, inform the anaesthesia team.
Contraindications: acute psychosis, severe narrow-angle glaucoma, severe heart failure, recent myocardial infarction with conduction disturbance, malignant melanoma.
Adherence: levodopa must be taken reliably, since even a missed dose can lead to motor worsening. Patients and relatives benefit from structured daily planning and weekly pill organisers.
Patient communication: the experience with levodopa is highly individual. Some benefit stably for years, others develop motor complications early. Honest counselling about the action profile and expected changes over the disease course supports patients in realistic therapy planning.
Related substances
- Levodopa, identical substance, standard spelling
- Benserazide, peripheral decarboxylase inhibitor
- Galantamine, cholinesterase inhibitor in dementia
- Memantine, NMDA antagonist in dementia
Frequently asked questions
L-dopa or levodopa?
Both refer to the same substance. L-dopa is the biochemically correct spelling indicating the levorotatory stereochemistry. Levodopa is the international substance name. In package inserts and SmPCs, levodopa is most often used.
Why can't I take L-dopa directly with food?
Protein-rich meals contain other large neutral amino acids that compete with L-dopa for the same transporter in the gut and at the blood-brain barrier. Taken together, absorption is markedly impaired and effect unstable. A pause of 30 to 60 minutes before, or 2 hours after, protein optimises the effect.
What are wearing off and dyskinesias?
Wearing off is the decrease of effect towards the end of a dosing interval with reappearance of Parkinson symptoms. Dyskinesias are involuntary, often choreiform movements that mostly occur at peak L-dopa effect. Both belong to late motor complications of long-term therapy and are caused not by L-dopa itself but by disease dynamics.
What are impulse-control disorders?
Under dopaminergic therapy, some patients develop new impulsive behaviour patterns, e.g. pathological gambling, excessive shopping, hypersexuality or compulsive eating. These symptoms are not rare and strongly affect the social environment. They should be actively asked about, since patients often remain silent out of shame. Adjusting therapy can bring relief.
Sources
- EMA European Medicines Agency
- BfArM Federal Institute for Drugs and Medical Devices
- AWMF S2k guideline idiopathic Parkinson's disease
- Gelbe Liste levodopa monograph
Legal notice and disclaimer
The information on this page is provided for general information purposes only and does not constitute medical advice, diagnosis or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medicines should only be used after a doctor's prescription or pharmacy supply. All information is based on summaries of product characteristics and accepted scientific sources at the time of writing; the current SmPC of the manufacturer is always decisive. Sanoliste accepts no liability for completeness, timeliness or accuracy. In a medical emergency, dial the emergency number 112.